Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II biomarker and trastuzumab-beyond-progression study in HER2-positive metastatic breast cancer
2008-004013-94Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and capecitabine in breast cancer, sponsored by Roche. Primary endpoints: Molecular biomarker signatures associated with trastuzumab sensitivity, Time to progression and 2 more. Started Sep 2009; status: terminated.
02
Drugs
trastuzumabcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-004013-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004013-94.